Recent Updates
Recently added Catalysts

Japanese encephalitis vaccine Hepatitis A vaccine

Phase 2

Japanese Encephalitis | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Oct 2, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials1
Total Enrollment300

FDA Designations

No designations recorded

Clinical trial landscape

Japanese encephalitis vaccine Hepatitis A vaccine · 1 trial · 2 indications

Phase 2 1
NCT00621764Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and ChildrenJapanese Encephalitis
COMPLETED300 Analytics
PHASE2COMPLETED
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Japanese EncephalitisUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection
Day 0 up to Day 14 post-vaccination

12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, \>39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, \>3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable. 2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, \>39˚C; Headache, Malaise, and Myalgia, Prevents activities.

Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as Second Injection
Day 0 up to Day 14 post-vaccination

12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, \>39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, \>3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable. 2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, \>39˚C; Headache, Malaise, and Myalgia, Prevents activities.

Secondary Endpoints

Percentage of Participants With Seroconversion to JE-CV Vaccine Antigens Following Administration of JE-CV Vaccination
Day 0 (pre-vaccination) and Day 28 after final vaccination
Summary of Geometric Mean Titers Against JE Antibodies Before and After JE-CV Vaccination
Day 0 (pre-vaccination) and Day 28 after final vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposePREVENTION

Treatment Arms

ArmTypeDescription
JE-CV/Hepatitis A (Group 1)EXPERIMENTALParticipants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
Hepatitis A/JE-CV (Group 2)EXPERIMENTALParticipants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
JE-CV/Hepatitis A (Group 3)EXPERIMENTALParticipants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
Hepatitis A/JE-CV (Group 4)EXPERIMENTALParticipants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)

Interventions

NameTypeDescription
Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)BIOLOGICAL≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)BIOLOGICAL0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
Unlock Study Design Details

Eligibility Criteria

Age Range12 Months to 5 Years
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: * Provision of consent form signed by at least one parent or another legally acceptable representative, and by at least one independent witness. * Completion of vaccinations according to the national immunization schedule * Subject and parent/legally acceptable representative ab...

Countries:Thailand
Unlock Eligibility Criteria